PRKD1 (Ab-910) Antibody

What is PRKD1 and what are its main biological functions?

PRKD1 (protein kinase D1) serves as a significant signaling molecule that converts transient diacylglycerol (DAG) signals into prolonged physiological effects downstream of PKC. It plays crucial roles in multiple cellular processes, including:

• Mediating resistance to oxidative stress through activation of NF-kappa-B

• Functioning as a major regulator in post-traumatic inflammation

• Coordinating communication between endothelium and polymorphonuclear neutrophils (PMNs)

• Modulating endothelial barrier stability and cell adhesion molecule expression

• Influencing tumor progression when silenced by promoter methylation in certain cancers

Research indicates that PRKD1 activation occurs in endothelial cells following trauma both in vitro and in vivo, with significant increases in pPRKD S910/S916-autophosphorylation observed after traumatic insult .

What epitope does the PRKD1 (Ab-910) Antibody recognize and in which applications is it validated?

The PRKD1 (Ab-910) Antibody specifically recognizes the phosphorylated serine residue at position 910 of the protein kinase D1. This antibody has been validated for multiple research applications including:

• Western blot analysis (demonstrated efficacy in extracts from HeLa, 293, and 3T3 cells)

• ELISA assays for quantitative protein detection

The antibody exhibits reactivity across human, mouse, and rat samples, making it versatile for cross-species research applications .

How should I optimize Western blot protocols when using PRKD1 (Ab-910) Antibody?

For optimal Western blot results with PRKD1 (Ab-910) Antibody, implement the following research-validated protocol:

• Sample preparation: Extract proteins using standard lysis buffers containing phosphatase inhibitors to preserve phosphorylation status.

• Protein loading: Load 20-40 μg of total protein per lane.

• Separation conditions: Use 8-10% SDS-PAGE gels for optimal resolution of PRKD1 (~115 kDa).

• Transfer parameters: Transfer to PVDF membrane at 100V for 90 minutes or 30V overnight at 4°C.

• Blocking: Use 5% BSA in TBST for 1 hour at room temperature to reduce background.

• Primary antibody incubation: Dilute PRKD1 (Ab-910) Antibody at 1:1000 in 5% BSA-TBST and incubate overnight at 4°C.

• Detection: Use HRP-conjugated secondary antibodies and enhanced chemiluminescence for visualization.

Research studies have successfully employed this antibody to detect PRKD activation in various cell types including HUVECs and 3T3 cells .

What are the recommended controls and validation approaches for PRKD1 (Ab-910) Antibody experiments?

To ensure experimental validity when using the PRKD1 (Ab-910) Antibody, incorporate these essential controls:

Positive controls:

• HeLa cell lysates treated with PMA (phorbol 12-myristate 13-acetate) to induce PRKD1 phosphorylation

• 293 or 3T3 cell extracts, which have demonstrated reliable signal with this antibody

Negative controls:

• Samples treated with alkaline phosphatase to remove phosphorylation

• PRKD1 knockdown cells generated using shRNA (as described in endothelial barrier studies)

Validation approaches:

• Parallel detection with total PRKD1 antibody to normalize phosphorylation levels

• Treatment with known PRKD inhibitors (CRT0066101 or Kb-NB-142-70) at 5 μM to confirm specificity

• Comparative analysis with alternative phospho-sites (S916) to confirm activation patterns

How can I effectively detect PRKD1 activation in tissue samples using immunohistochemistry?

For successful immunohistochemical detection of activated PRKD1 in tissue samples, follow this evidence-based methodology:

• Tissue preparation: Fix tissues in 4% paraformaldehyde and prepare paraffin or frozen sections (5-7 μm thickness).

• Antigen retrieval: Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes.

• Blocking: Block with 5% normal serum from the species of secondary antibody for 1 hour.

• Co-staining approach: Implement dual immunofluorescence with:

  • PRKD1 (Ab-910) Antibody (1:100 dilution)

  • Cell-type specific markers (e.g., CD34 for endothelial cells)

• Detection: Use fluorescently-labeled secondary antibodies with appropriate controls.

• Analysis: Perform confocal microscopy with equal settings across samples, utilizing ROI analysis for quantification.

This approach has been successfully employed to detect PRKD activation in lung microvascular endothelial cells after polytrauma with hemorrhagic shock, revealing significant increases in pPRKD immunofluorescence co-localized with endothelial markers .

How does PRKD1 regulate endothelial barrier function and how can this be experimentally assessed?

PRKD1 functions as a critical regulator of endothelial barrier integrity through multiple mechanisms:

Molecular mechanisms:

• Modulation of VE-cadherin and β-catenin at adherens junctions

• Regulation of actin cytoskeleton organization and dynamics

• Influence on cellular adhesion molecule expression via NFκB signaling

Experimental assessment methodologies:

Research indicates that PRKD inhibition with CRT0066101 or Kb-NB-142-70 (5 μM) significantly enhances basal endothelial barrier stability and reverses barrier destabilization induced by thrombin or inflammatory mediators .

What is the relationship between PRKD1 and epigenetic regulation in cancer progression?

The relationship between PRKD1 and epigenetic regulation represents an emerging area of cancer research with significant therapeutic implications:

Epigenetic silencing mechanisms:

• PRKD1 promoter undergoes aberrant methylation in invasive breast cancer cells

• Methylation increases with tumor aggressiveness, correlating with cancer progression

• DNA methyltransferase activity mediates this silencing

Experimental approaches for investigation:

• Methylation analysis:

  • Reduced representation bisulfite deep sequencing

  • Methylation-specific PCR (MSP-PCR)

  • In situ MSP-PCR for tissue samples

• Reexpression strategies:

  • Treatment with DNA methyltransferase inhibitor decitabine

  • Validation of reexpression by RT-PCR, immunoblotting, and immunohistochemistry

• Functional assessments:

  • Transwell invasion assays to measure cell invasiveness

  • In vivo tumor growth and metastasis monitoring using imaging systems

Research demonstrates that reversion of PRKD1 promoter methylation restores PKD1 expression and effectively blocks tumor spread and metastasis to the lung in a PKD1-dependent manner .

How does PRKD1 influence inflammatory signaling pathways and leukocyte recruitment?

PRKD1 orchestrates inflammatory responses through complex signaling networks:

Signaling pathways regulated by PRKD1:

• NFκB activation (demonstrated by increased pP65 S536-phosphorylation)

• Transcriptional regulation of adhesion molecules (ICAM-1, VCAM-1, SELE)

• Modulation of inflammatory cytokine production (IL6, CXCL8, IL1β)

Experimental methods to assess PRKD1-mediated inflammation:

• Gene expression analysis:

  • qPCR for adhesion molecules and inflammatory mediators

  • Primers for ICAM-1, VCAM-1, SELE, IL6, CXCL8, IL1β

  • PCR conditions: 1 min at 55°C, 1-min extension at 72°C for 35 cycles

• Protein secretion measurement:

  • ELISA for IL6 and CXCL8 in cell supernatants

  • Western blot analysis for signaling components

• Functional leukocyte recruitment assays:

  • Transmigration assays using fMLP-stimulated PMNs

  • CellTracker-labeled neutrophils traversing endothelial monolayers

Research demonstrates that PRKD inhibition or knockdown significantly reduces inflammatory gene expression and subsequent neutrophil transmigration through endothelial monolayers, highlighting PRKD1's role as a critical modulator of inflammation .

What are common technical challenges when using PRKD1 (Ab-910) Antibody and how can they be resolved?

Researchers may encounter several technical challenges when working with PRKD1 (Ab-910) Antibody:

Challenge: Weak or inconsistent signal in Western blots
Solutions:

• Ensure proper sample handling to preserve phosphorylation (immediate processing with phosphatase inhibitors)

• Optimize antibody concentration (1:500-1:1000 dilution range)

• Extend exposure time for detection of low abundance phosphorylated protein

• Implement signal enhancement systems (biotin-streptavidin amplification)

Challenge: Cross-reactivity with related kinases
Solutions:

• Include appropriate controls (PRKD1 knockdown samples)

• Verify specificity with alternative detection methods

• Pre-adsorb antibody with blocking peptides when necessary

Challenge: Variable results across different sample types
Solutions:

• Standardize protein extraction protocols

• Normalize to total PRKD1 levels

• Consider cell/tissue-specific optimization of immunoprecipitation conditions

Challenge: Difficulty detecting in fixed tissues
Solutions:

• Test multiple antigen retrieval methods (citrate, EDTA, enzymatic)

• Optimize antibody concentration for immunohistochemistry (typically 1:50-1:200)

• Implement signal amplification systems for low abundance targets

How should researchers interpret PRKD1 activation patterns in different experimental contexts?

Interpreting PRKD1 activation requires careful consideration of experimental context and activation kinetics:

Activation kinetics considerations:

• PRKD activation follows stimulus-specific temporal patterns

• In HUVECs, PTC (polytrauma cocktail) induces sustained activation over several hours

• Thrombin triggers rapid but transient activation peaking within minutes

Context-dependent interpretation framework:

Validation strategies:

• Multiple phospho-site analysis (S910 and S916)

• Correlation with functional readouts (barrier integrity, gene expression)

• Pharmacological intervention (PRKD inhibitors) to confirm causality

What are emerging applications of PRKD1 research in precision medicine?

PRKD1 research offers promising avenues for translational medicine, particularly in developing targeted therapies for:

Inflammatory disorders:

• PRKD1 inhibition could potentially limit excessive neutrophil infiltration in acute inflammatory conditions

• Targeting the PRKD1-NFκB axis may reduce inflammatory cytokine production

• Endothelial barrier stabilization through PRKD1 modulation might prevent vascular leakage in trauma

Cancer therapeutics:

• Epigenetic reactivation of silenced PRKD1 represents a potential strategy for limiting cancer invasion

• DNA methyltransferase inhibitors (e.g., decitabine) restore PRKD1 expression and reduce metastatic potential

• PRKD1 status might serve as a biomarker for tumor aggressiveness and therapeutic responsiveness

Future research directions:

• Development of targeted PRKD1 modulators with improved specificity

• Identification of tissue-specific roles of PRKD1 in disease pathogenesis

• Integration of PRKD1 status in personalized treatment approaches

How can researchers combine genetic and pharmacological approaches to study PRKD1 function?

A comprehensive understanding of PRKD1 requires complementary experimental strategies:

Genetic manipulation approaches:

• shRNA-mediated knockdown (as demonstrated in endothelial barrier studies)

• CRISPR-Cas9 genome editing for complete knockout or point mutations

• Inducible expression systems for temporal control

• Knockdown-rescue experiments to confirm specificity (verify with qPCR and Western blot)

Pharmacological intervention strategies:

• Selective PRKD inhibitors:

  • CRT0066101 (IC50: 1 nM for PRKD1, 2.5 nM for PRKD2, 2 nM for PRKD3)

  • Kb-NB-142-70 (IC50: 28.3±2.3 nM for PRKD1, 58.7±4.2 nM for PRKD2, 53.2±3.5 nM for PRKD3)

• Epigenetic modulators (decitabine) for reexpression studies

• NFκB pathway inhibitors (BAY 11-7082) to dissect downstream signaling

Integrated experimental design:

• Establish baseline PRKD1 function through genetic approaches

• Validate with selective pharmacological tools

• Implement rescue experiments to confirm specificity

• Translate findings to physiologically relevant models (3D culture, organoids, animal models)

By integrating these approaches, researchers can develop a comprehensive understanding of PRKD1 biology while minimizing experimental artifacts associated with any single methodology.